Syfovre approval for geographic atrophy tops retina news in 2023
Click Here to Manage Email Alerts
Healio’s top retina items last year included the FDA approvals of Syfovre for geographic atrophy and Eylea HD for wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy.
Check out the most popular retina/vitreous items from 2023 below.
Image: Adobe Stock
FDA approves Syfovre – first treatment for geographic atrophy, a leading cause of blindness
Apellis Pharmaceuticals announced the FDA approved its product Syfovre, also known as pegcetacoplan injection, for the treatment of geographic atrophy secondary to age-related macular degeneration. Read more.
FDA approves Eylea HD
The FDA approved Eylea HD, an 8 mg aflibercept injection, to treat wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy, according to a press release from Regeneron. Read more.
Dietary nitrate intake may be associated with lower AMD risk
Dietary nitrate intake was associated with a lower risk for age-related macular degeneration, but the association may be attributed to existing Mediterranean diet patterns, according to a cohort study. Read more.
Macular thickness mapping detects hydroxychloroquine toxicity early, with specificity
Sequential macular thickness mapping can be used to detect retinal toxicity from hydroxychloroquine early and with specificity. Read more.
Patients come first even as reimbursement decreases for vitreoretinal procedures
Despite decreases in reimbursement for vitreoretinal procedures, surgeons should still prioritize doing what is best for the patient, according to a speaker at Retina 2023. Read more.
Collapse
Healio Coverage
Click Here to Manage Email Alerts